FDA accepts Lilly-Boehringer Ingelheim’ sNDA for Jardiance
Pharmaceutical Technology
JANUARY 22, 2023
Eli Lilly and Company and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets for chronic kidney disease (CKD) in adult patients. Jardiance is currently being evaluated as a potential therapy for reducing kidney disease progression and cardiovascular death risk in CKD adult patients.
Let's personalize your content